JP2020054368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020054368A5 JP2020054368A5 JP2019220462A JP2019220462A JP2020054368A5 JP 2020054368 A5 JP2020054368 A5 JP 2020054368A5 JP 2019220462 A JP2019220462 A JP 2019220462A JP 2019220462 A JP2019220462 A JP 2019220462A JP 2020054368 A5 JP2020054368 A5 JP 2020054368A5
- Authority
- JP
- Japan
- Prior art keywords
- lactamase
- polar
- lactamase according
- hydrophilic residue
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461980844P | 2014-04-17 | 2014-04-17 | |
| US61/980,844 | 2014-04-17 | ||
| US201462046627P | 2014-09-05 | 2014-09-05 | |
| US62/046,627 | 2014-09-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016562248A Division JP6685925B2 (ja) | 2014-04-17 | 2015-04-17 | 治療用として改善された特性を有するβ−ラクタマーゼ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020054368A JP2020054368A (ja) | 2020-04-09 |
| JP2020054368A5 true JP2020054368A5 (https=) | 2020-08-06 |
| JP7038094B2 JP7038094B2 (ja) | 2022-03-17 |
Family
ID=54321063
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016562248A Expired - Fee Related JP6685925B2 (ja) | 2014-04-17 | 2015-04-17 | 治療用として改善された特性を有するβ−ラクタマーゼ |
| JP2019220462A Expired - Fee Related JP7038094B2 (ja) | 2014-04-17 | 2019-12-05 | 治療用として改善された特性を有するβ－ラクタマーゼ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016562248A Expired - Fee Related JP6685925B2 (ja) | 2014-04-17 | 2015-04-17 | 治療用として改善された特性を有するβ−ラクタマーゼ |
Country Status (10)
| Country | Link |
|---|---|
| US (14) | US9290754B2 (https=) |
| EP (1) | EP3132033B1 (https=) |
| JP (2) | JP6685925B2 (https=) |
| KR (1) | KR102360582B1 (https=) |
| CN (1) | CN106163546B (https=) |
| AU (1) | AU2015247382B2 (https=) |
| BR (1) | BR112016023360B1 (https=) |
| CA (1) | CA2942971C (https=) |
| RU (1) | RU2678124C2 (https=) |
| WO (1) | WO2015161243A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057744A1 (en) | 2014-10-08 | 2016-04-14 | Synthetic Biologics, Inc. | Beta-lactamase formulations and uses thereof |
| EP3265119B1 (en) * | 2015-03-06 | 2023-10-11 | Theriva Biologics, Inc. | Safe and effective beta-lactamase dosing for microbiome protection |
| JP6845258B6 (ja) * | 2016-02-23 | 2021-04-28 | ダ・ボルテラ | ベータ−ラクタマーゼ変異体 |
| WO2017144495A1 (en) * | 2016-02-23 | 2017-08-31 | Da Volterra | Beta-lactamase variants |
| CN109562147B (zh) | 2016-06-28 | 2023-09-01 | 特里瓦生物制剂有限公司 | 保护微生物组免受口服抗生素 |
| US20210290741A1 (en) | 2018-08-05 | 2021-09-23 | Da Volterra | Compositions for the treatment of graft versus host disease |
| AU2019317986A1 (en) | 2018-08-05 | 2021-02-11 | Da Volterra | Method for improving anticancer agent efficacy |
| CN109576250B (zh) * | 2018-12-26 | 2025-04-15 | 广州白云山拜迪生物医药有限公司 | 一种酶活提高的头孢菌素酶突变体及其构建方法 |
| CN109337889B (zh) * | 2018-12-26 | 2020-10-02 | 广州白云山拜迪生物医药有限公司 | 一种酶活提高的金属β-内酰胺酶突变体及其构建方法 |
| CA3136833A1 (en) * | 2019-05-06 | 2020-11-12 | Synthetic Biologics, Inc. | Beta-lactamase compositions for treatment of graft versus host disease |
| EP4148136A1 (en) | 2021-09-08 | 2023-03-15 | Da Volterra | An engineered yeast cell for the delivery of antibiotic-inactivating enzymes |
| WO2024012487A1 (en) * | 2022-07-14 | 2024-01-18 | The Hong Kong Polytechnic University | Biosensor comprising a modified beta-lactamase and uses thereof |
| CN115433701B (zh) * | 2022-11-08 | 2023-03-17 | 南京农业大学 | 一株变形杆菌及其菌剂和在降解头孢类抗生素中的应用 |
| CN117701543A (zh) * | 2023-12-15 | 2024-03-15 | 四川省固体废物与化学品管理中心 | 一种b家族内酰胺酶突变体及其固定化方法与应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL89987C (https=) | 1954-05-29 | |||
| US2941995A (en) | 1957-08-02 | 1960-06-21 | Beecham Res Lab | Recovery of solid 6-aminopenicillanic acid |
| US2982696A (en) | 1959-05-01 | 1961-05-02 | Schenley Ind Inc | Ion-exchange procedures for the purification of penicillinase |
| US3070511A (en) | 1960-02-10 | 1962-12-25 | Lepetit Spa | Process for preparing 6-aminopenicillanic acid |
| US3150059A (en) | 1962-12-26 | 1964-09-22 | Lilly Co Eli | Penicillin deacylation via actinoplanaceae fermentation |
| US3239394A (en) | 1964-06-15 | 1966-03-08 | Merck & Co Inc | Process for producing 7-amino-cephalosporanic acid |
| US3499909A (en) | 1966-05-18 | 1970-03-10 | Koninklijke Gist Spiritus | Process for production of 6-aminopenicillanic acid |
| US3488729A (en) | 1966-08-22 | 1970-01-06 | Lilly Co Eli | Cephalothin ester |
| GB1241844A (en) | 1968-08-23 | 1971-08-04 | Beecham Group Ltd | Penicillins |
| FI59265C (fi) | 1974-08-13 | 1981-07-10 | Beecham Group Ltd | Foerfarande foer framstaellning av 6-aminopenicillansyra |
| GB1463513A (en) | 1974-08-13 | 1977-02-02 | Beecham Group Ltd | Enzymes |
| GB2199582A (en) | 1987-01-07 | 1988-07-13 | Bayer Ag | Analogues of pancreatic secretory trypsin inhibitor |
| FR2613624B1 (fr) | 1987-04-10 | 1990-11-23 | Roussy Inst Gustave | Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines |
| CA2007083A1 (en) | 1989-01-09 | 1990-07-09 | Nobuhiko Katunuma | Pharmaceutical use of trypstatin |
| CS275231B2 (en) | 1989-09-29 | 1992-02-19 | Ustav Makormolekularni Chemie | Medicine bottle |
| FI920206A0 (fi) | 1992-01-17 | 1992-01-17 | Pekka Untamo Heino | Medicinsk anvaendning, medicinskt foerfarande och preparat. |
| CN1190434A (zh) | 1995-07-07 | 1998-08-12 | 诺沃挪第克公司 | 用不能形成芽孢的芽孢杆菌生产蛋白质的方法 |
| CN1363680A (zh) * | 2001-01-05 | 2002-08-14 | 上海博德基因开发有限公司 | 一种新的多肽——β内酰胺酶20.24和编码这种多肽的多核苷酸 |
| US7585674B2 (en) | 2001-05-29 | 2009-09-08 | Kao Corporation | Host microorganisms |
| FI112666B (fi) | 2001-11-06 | 2003-12-31 | Ipsat Therapies Oy | Itiöimätön Bacillus subtilis, sen valmistus ja käyttö |
| FR2843302B1 (fr) | 2002-08-09 | 2004-10-22 | Centre Nat Rech Scient | Forme galenique pour la delivrance colique de principes actifs |
| EP2284185A3 (en) * | 2004-01-09 | 2011-05-18 | Novozymes A/S | Bacillus protein inactivation |
| EP1564286A1 (en) * | 2004-02-11 | 2005-08-17 | Université de Liège | Hybrid proteins of beta-lactamase class A |
| DE102004032995A1 (de) * | 2004-07-08 | 2006-03-30 | Henkel Kgaa | Neue, sekretierte Genprodukte von Bacillus licheniformis und darauf aufbauende verbesserte biotechnologische Produktionsverfahren |
| ES2429095T3 (es) | 2005-05-18 | 2013-11-13 | Da Volterra | Aporte colónico de adsorbentes |
| FI119190B (fi) * | 2006-06-21 | 2008-08-29 | Ipsat Therapies Oy | Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi |
| CN101104858A (zh) * | 2006-07-10 | 2008-01-16 | 温州医学院 | 一种体外定向进化获取高活力超广谱β-内酰胺酶的方法 |
| FI119678B (fi) | 2006-11-28 | 2009-02-13 | Ipsat Therapies Oy | Beta-laktamaasin käyttö |
| US20100064393A1 (en) * | 2006-11-29 | 2010-03-11 | Novozymes, Inc. | Bacillus liceniformis chromosome |
| CN101647022B (zh) * | 2007-01-31 | 2012-07-18 | 麦科罗医药科技(武汉)有限公司 | 描述蛋白质的构象和根据折叠、整体形状与结构序列对其进行评价的方法、系统及装置 |
| FI20105572A0 (fi) | 2010-05-24 | 2010-05-24 | Prevab R Lcc | Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt |
| US9347057B2 (en) * | 2012-06-12 | 2016-05-24 | The Johns Hopkins University | Methods for efficient, expansive user-defined DNA mutagenesis |
-
2015
- 2015-04-17 BR BR112016023360-3A patent/BR112016023360B1/pt active IP Right Grant
- 2015-04-17 RU RU2016140627A patent/RU2678124C2/ru active
- 2015-04-17 EP EP15780157.2A patent/EP3132033B1/en active Active
- 2015-04-17 CA CA2942971A patent/CA2942971C/en active Active
- 2015-04-17 KR KR1020167027846A patent/KR102360582B1/ko active Active
- 2015-04-17 US US14/689,877 patent/US9290754B2/en active Active
- 2015-04-17 CN CN201580019029.7A patent/CN106163546B/zh not_active Expired - Fee Related
- 2015-04-17 JP JP2016562248A patent/JP6685925B2/ja not_active Expired - Fee Related
- 2015-04-17 WO PCT/US2015/026457 patent/WO2015161243A2/en not_active Ceased
- 2015-04-17 AU AU2015247382A patent/AU2015247382B2/en not_active Ceased
-
2016
- 2016-02-09 US US15/019,474 patent/US9376673B1/en active Active
- 2016-05-20 US US15/160,669 patent/US9404103B1/en active Active
- 2016-07-01 US US15/200,508 patent/US9464280B1/en active Active
- 2016-08-24 US US15/245,517 patent/US9695409B2/en active Active
-
2017
- 2017-06-02 US US15/611,881 patent/US9783797B1/en not_active Expired - Fee Related
- 2017-08-10 US US15/674,177 patent/US10011824B2/en active Active
-
2018
- 2018-05-30 US US15/993,159 patent/US10087433B1/en active Active
- 2018-08-24 US US16/112,283 patent/US10336995B2/en active Active
-
2019
- 2019-05-16 US US16/414,411 patent/US10584326B2/en active Active
- 2019-12-05 JP JP2019220462A patent/JP7038094B2/ja not_active Expired - Fee Related
-
2020
- 2020-01-24 US US16/751,734 patent/US10767171B2/en active Active
- 2020-07-24 US US16/938,318 patent/US11236319B2/en active Active
-
2021
- 2021-12-08 US US17/545,050 patent/US11608494B2/en active Active
-
2023
- 2023-02-07 US US18/165,470 patent/US20230313166A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020054368A5 (https=) | ||
| JP2017515466A5 (https=) | ||
| RU2012155420A (ru) | Бета-лактамаза, способ ее модификации, получения и применение | |
| CN103648496B (zh) | 包含β-内酰胺抗生素、舒巴坦和β-内酰胺酶抑制剂的药物组合物 | |
| US6627625B1 (en) | Treatment of behavioral disorders with β-lactam compounds | |
| JP2010511020A (ja) | ベータ−ラクタマーゼの使用 | |
| RU2013155902A (ru) | Производные 1,6-диазабицикло [3,2,1] октан-7-она и их применение при лечении бактериальных инфекционных болезней | |
| KR20160144996A (ko) | 치료법을 위한 개선된 특성을 지니는 베타-락타마제 | |
| CN102548999A (zh) | 含有取代的含氮稠杂环的头孢菌素衍生物 | |
| JP2021505620A5 (https=) | ||
| Doern et al. | In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods | |
| CA2003340A1 (en) | Pharmaceutical compositions | |
| WO2021005059A1 (en) | Modified escherichia coli strain nissle and treatment of gastrointestinal disorder | |
| EP3033352A1 (en) | Linear peptide antibiotics | |
| ES2367151T3 (es) | Derivados de tioxanteno como únicos agentes anti-infecciosos para el uso en el tratamiento de enfermedades infecciosas. | |
| RU2016113755A (ru) | Азотсодержащие соединения и их применение | |
| CN118126132B (zh) | 多肽及其与头孢噻肟舒巴坦的组合 | |
| US8604059B2 (en) | Thioxanthene derivatives for the treatment of infectious diseases | |
| Vilvanathan | Penicillins, Cephalosporins, and Other b-Lactam Antibiotics | |
| CN101948909A (zh) | 一种细菌ⅰ型、ⅱ型、ⅲ型整合子基因的pcr检测方法 | |
| CN113712975B (zh) | 氨磷汀作为ndm-1抑制剂或抗生素保护剂的新用途 | |
| WO1995017184A1 (en) | Pharmaceutical compositions containing ceftriaxone and penems | |
| WO2012118124A1 (ja) | 新規ケモカイン受容体拮抗剤 | |
| Kaleko et al. | P4A, a Novel Oral β-Lactamase for the Prevention of Cephalosporin-Induced C. difficile Infection | |
| Pezzani | Cefuroxime |